- In February 2023, GSK plc announced that the U.S. Food and Drug Administration (FDA) granted full approval for Jemperli, intended for the treatment of adult patients with recurrent or advanced endometrial cancer characterized by mismatch repair deficiency (dMMR)
- In September 2022, Lynparza was approved in China as the first-line maintenance treatment in combination with bevacizumab for advanced ovarian cancer positive for homologous recombination deficiency (HRD)
- In July 2023, GSK plc announced that the U.S. Food and Drug Administration (FDA) had granted approval for Jemperli (Dostarlimab) to be used in combination with carboplatin and paclitaxel, followed by Jemperli as a monotherapy for treatment of adult patients with primary advanced or recurrent endometrial cancer characterized by mismatch repair deficiency (dMMR), as confirmed by an FDA-approved test, or microsatellite instability-high (MSI-H)
- In May 2023, Astellas Pharma Inc., led by President and CEO Naoki Okamura, announced that the U.S. Food and Drug Administration (FDA) has approved VEOZAHTM (Fezolinetant) at a dosage of 45 mg once daily for the treatment of moderate to severe vasomotor symptoms (VMS) associated with menopause. VEOZAH is notable for being the first nonhormonal neurokinin 3 (NK3) receptor antagonist to receive approval for this purpose
- In June 2021, Organon proudly announced its launch as the sole global company of its size dedicated to women's health. The familiar name of Organon has returned, marking a positive development for women worldwide and for pharmaceutical manufacturing in the Netherlands and Belgium, where the global healthcare company operates two production facilities and two office locations
Frequently Asked Questions
The market is segmented based on Segmentation, By Disease Type (Gynecological Cancer, Polycystic Ovarian Syndrome (PCOS), Genital Tract Infection, Endometriosis, Ovarian Cyst, Contraception and Others), Therapy Type (Hormonal, Non-Hormonal and Others), Population Type (Adolescent and Adults), Drug Type (Branded and Generics), Route of Administration (Oral, Parenteral, Intravaginal and Others), End User (Hospitals, Specialty Clinics, Diagnostic Centers, Research Institute, and Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, online Pharmacies and Others) – Industry Trends and Forecast to 2031
.
The Global Gynecological Drugs Market size was valued at USD 65.42 USD Billion in 2023.
The Global Gynecological Drugs Market is projected to grow at a CAGR of 3.2% during the forecast period of 2024 to 2031.
The market report covers data from the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E., South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
